Evaluation of LncRNAs CBR3-AS1 and PCA3 expression in Gastric cancer and their correlation to clinicopathological variables
Parisa Najari1, Sama Akbarzadeh2,3, Ali Rajabi1, Samaneh Tayefeh-Gholami1, Elaheh Malek Abbaslou1, Tooraj Ghasemzadeh1, Mohammadali Hosseinpourfeizi1 and Reza Safaralizadeh1
1 Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
2 Department of Biophysics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
3 Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkey
Correspondence to:
Reza Safaralizadeh, email: [email protected]
Keywords: GC; LncRNAs; CBR3-AS1; PCA3; qRT-PCR
Received: January 21, 2025 Accepted: April 29, 2025 Published: May 09, 2025
Abstract
Background: Gastric cancer (GC) is a multifactorial disease with a high death rate due to the unknown mechanisms involved in the developing, progressing, and late diagnosing GC. Several cancers have been linked to Long non-coding RNAs (lncRNAs), including GC, through differential expression. They play a crucial role in tumorigenesis pathways as modulatory factors, making them intriguing clinical and diagnostic biomarkers for many malignancies. This study’s objective is to compare the lncRNAs CBR3-AS1 and PCA3 expression levels in tumoral tissues to marginal tissues and the clinicopathological features of patients.
Methods and Results: 100 GC patients’ tumoral and marginal tissue samples from Tabriz’s Valiasr Hospital were gathered for this case-control research. To determine the expression level of PCA3 and CBR3-AS1 lncRNAs in GC, total RNA was extracted, and the qRT-PCR technique was employed. Compared to adjacent marginal tissues, the tumor tissue of patients with GC showed a significant increase in the expression levels of PCA3 and CBR3-AS1 (P < 0.0001). The expression ratio of lncRNA CBR3-AS1 and PCA3 did not significantly correlate with clinicopathological variables. The ROC curve’s findings lead to the conclusion that the genes lncRNAs PCA3 and CBR3-AS1, with AUC values of 0.68 and 0.79, respectively, suggest that they could play carcinogenic roles in GC and may act as moderate diagnostic biomarkers for GC.
Conclusions: In GC, CBR3-AS1 and PCA3 may be utilized as therapeutic targets and prognostic biomarkers, respectively.
PII: 241
